Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Status Completed

Clinical Trial Summary

ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.

Clinical Trial Description

The current low cure rates in most patients with advanced hematologic cancers indicate the need to identify new agents that can be incorporated with current therapies to improve prognosis. The vinca alkaloids are effective broad-spectrum anti-leukemic drugs. Microtubules are a major structural component of cells. They play a role in cell shape, cellular polarity, cellular movement, intracellular transport and the segregation of chromosomes during mitosis. The cellular microtubule dynamics are highly regulated. As cells enter mitosis, the interphase microtubules disappear and are replaced with a new network of microtubules that interact with the mitotic spindle. Disruption of these new microtubules leads to cell cycle arrest. These important and highly labile microtubule arrays comprising the mitotic spindle are the principal target of oncologic antimitotic compounds. Known antimitotic agents fall into three classes, the vinca alkaloids (vincristine, vinblastine, and vinorelbine), taxanes (paclitaxel and docetaxel), and colchicine-site binders. There are no colchicine-site agents currently approved for cancer chemotherapy. These three classes of compounds have distinct binding sites on the tubulin subunits. ABT-751 is a novel orally administered antimitotic agent that binds to the colchicine site on beta-tubulin and inhibits polymerization of microtubules. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00047489
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase	Phase 1
Start date	December 2002
Completion date	January 2005

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03248479` - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies	Phase 1
Recruiting	`NCT05454241` - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies	Phase 2
Recruiting	`NCT06041815` - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting	`NCT05005442` - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)	Phase 2
Recruiting	`NCT02300571` - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant	N/A
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Completed	`NCT01162096` - Reduced Intensity Haploidentical Transplant for Hematological Malignancies	Phase 1/Phase 2
Terminated	`NCT00506948` - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)	Phase 2
Completed	`NCT00379587` - Rituximab for Prevention of Chronic GVHD	Phase 1/Phase 2
Active, not recruiting	`NCT04557098` - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma	Phase 2
Recruiting	`NCT04283097` - Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects	Phase 1
Completed	`NCT03067155` - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.	Phase 2
Completed	`NCT01725555` - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors	Phase 1
Completed	`NCT00438178` - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies	Phase 1
Completed	`NCT03711604` - Compassionate Use Study of Tenalisib (RP6530)	Phase 1/Phase 2
Withdrawn	`NCT01168882` - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies	Phase 1
Completed	`NCT01246206` - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT	Phase 2
Completed	`NCT01172132` - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"	N/A
Completed	`NCT00506402` - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT00163644` - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT	N/A